UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549



FORM 10-K/A

Amendment No. 1



(Mark One)ý

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2010oro

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period
from                                  to


Commission File Number 000-51708



REDPOINT BIO CORPORATION(Exact name of registrant as specified in its charter)



Delaware(State or other jurisdiction of
incorporation or organization)

22-3393959(I.R.S. Employer Identification No.)7 Graphics Drive
Ewing, New Jersey(Address of principal executive offices)

08628(Zip Code)


Registrant's
telephone number, including area code:(609) 637-9700



Securities
registered pursuant to Section 12(b) of the Act:None.

Securities
registered pursuant to Section 12(g) of the Act:

Title of ClassCommon Stock, $.0001 par value per share




Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. o Yes    ý No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the
Act. o Yes    ý No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. ý Yes    o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). o Yes    o No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter)
is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. ý

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer o

Non-accelerated filer o (Do not check if a
smaller reporting company)

Smaller reporting company ý


Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act). o Yes    ý No

The aggregate market value of the registrant's voting shares of common stock held by non-affiliates of the registrant on June 30, 2010, based on
a $0.20 per share, the last reported sale price on the OTC Bulletin Board on that date, was approximately $11,094,854.

The
number of shares of common stock, $0.0001 par value, of the registrant outstanding as of April 29, 2011 was 79,914,789 shares.

DOCUMENTS INCORPORATED BY REFERENCE

None.



---



TABLE OF CONTENTS



Item



PagePART III

10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

311.

EXECUTIVE COMPENSATION

812.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

2113.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

2314.

PRINCIPAL ACCOUNTING FEES AND SERVICES

24PART IV

15.

EXHIBITS, FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES

26SIGNATURES

27EXHIBIT INDEX

28


2

---





Table of Contents

EXPLANATORY NOTE

Redpoint Bio Corporation ("we", "our" and "us") is filing this Amendment No. 1 on Form 10-K/A to amend its
Annual Report on Form 10-K for the year ended December 31, 2010, filed on March 4, 2010. The purpose of this Form 10-K/A, Amendment No. 1 is
to include information required in Part III (Items 10, 11, 12, 13 and 14), that was to be incorporated by reference from our definitive proxy statement pursuant to Regulation 14A
of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Other
than the furnishing of the information identified above, this report does not modify or update the disclosure in the Form 10-K in any way. In addition, as
required by Rule 12b-15 under the Exchange Act, new certifications by our principal executive officer and principal financial officer are filed as exhibits to this
Form 10-K/A under Item 15 of Part IV hereof.

PART III

ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

Our Executive Officers and Directors

The following table identifies our current executive officers and directors:

Name

Age

Capacities in Which Served

In Current
Position SinceF. Raymond Salemme, Ph.D.(1)


65

President, Chief Executive Officer and Director

2007Scott M. Horvitz(2)


52

Chief Financial Officer, Treasurer and Secretary

2007Richard P. Shanley, CPA(3)


63

Chairman of the Board

2007Robert Chefitz(4)


51

Director

2007Leif Kjaergaard, Ph.D.(5)


64

Director

2007Allen Bloom, Ph.D.(6)


67

Director

2007Irwin Scher, M.D.(7)


71

Director

2007


(1)F. Raymond Salemme, Ph.D.became Robcor's President on April 20, 2007 and Robcor's Chief Executive
Officer and director on March 12, 2007. Dr. Salemme has been the Chief Executive Officer of Original Redpoint since June 2004. From April 2003 to December 2003, Dr. Salemme was
engaged by Johnson & Johnson Pharmaceuticals as a consultant to assist management with the acquisition of 3-Dimensional Pharmaceuticals, Inc., or 3DP, a publicly traded
biotechnology company founded in 1993, and acquired by Johnson & Johnson in 2003. Dr. Salemme was the founder of 3DP, and from February 1993 to April 2003, Dr. Salemme served in
various positions at 3DP, including President and Chief Scientific Officer. Dr. Salemme established and directed the technical, operating, business and financing strategies leading to 3DP's
initial public offering in 2000, and was co-inventor on 24 of 3DP's key technology patents. Prior to 3DP, Dr. Salemme directed research groups for biophysics, computational
chemistry, and structure-based drug design at Sterling Winthrop Pharmaceuticals and DuPont Merck Pharmaceuticals. Prior to DuPont Merck, he worked at DuPont Central Research, where he directed
molecular design teams involved in the discovery of new pharmaceuticals, agrochemicals, and engineered biopolymers. Dr. Salemme joined DuPont from Genex Corporation, one of the first
biotechnology companies, where he pioneered the use of X-ray crystallography and computer-aided molecular design for engineering proteins with novel or enhanced functional properties.
Prior to Genex, Dr. Salemme was Professor of Chemistry and Biochemistry at the University of Arizona, where he worked in the area of structural proteomics and determined the 3D
X-ray structures of several proteins involved in biological electron transfer. Dr. Salemme holds a B.A. in Molecular Biophysics from Yale


3

---



Table of Contents

University
and a Ph.D. in Chemistry from the University of California at San Diego. Dr. Salemme participates in various advisory committees, is a founder at Imiplex LLC, a nanotechnology
company, and a Board member at Via, a healthcare data analysis company and ExSar, a protein analysis company. (2)Scott M. Horvitzbecame Robcor's Chief Financial Officer, Treasurer and Secretary on March 12, 2007.
Mr. Horvitz has been Original Redpoint's Chief Financial Officer, Corporate Secretary and Treasurer since July 2004. Mr. Horvitz has approximately 25 years of experience in
accounting and financial management of biotechnology companies, including the management of initial public offerings with his two previous companies. Prior to becoming Chief Financial Officer of
Original Redpoint, Mr. Horvitz was a consultant to Original Redpoint from August 2003 to June 2004. Previously, Mr. Horvitz co-founded 3-Dimensional
Pharmaceuticals, Inc. where he worked from September 1993 until its acquisition by Johnson & Johnson in July 2003, most recently serving as its Chief Financial Officer and Corporate
Secretary and Treasurer. Prior to 3DP, Mr. Horvitz was the Executive Director of Finance and Human Resources with Magainin Pharmaceuticals. Mr. Horvitz holds a B.S. in Accounting from
the University at Albany and is a Certified Public Accountant. Mr. Horvitz served on the Board of Directors of Protez Pharmaceuticals, Inc. and was the Chairman of its Audit Committee
from 2004 until its acquisition by Novartis in 2008.(3)Richard P. Shanley, CPAwas appointed as a director on September 12, 2007, and as Chairman of the
Board on February 23, 2010. Mr. Shanley, a Certified Public Accountant in New York, retired from public accounting at the end of 2006, having completed a 31 year career at
Deloitte & Touche LLP and Eisner LLP, with a combined total of 25 years as a Partner at the two firms. During his career, Mr. Shanley served as lead audit partner on
numerous engagements for both public and private companies, including those requiring application of Sarbanes-Oxley Section 404, as well as public stock offerings, primarily for biotechnology,
pharmaceutical and high-tech companies. Mr. Shanley is a recognized authority on financing for emerging growth companies and is a published author of Financing Technology's Frontier. He has spoken
at industry meetings and is actively involved in organizations including the Biotech Council of New
Jersey, the New York Biotechnology Association, the Connecticut Venture Group, the Biotechnology Industry Organization, and others. Mr. Shanley is currently serving as the chair of the New York
State Society of CPA's Professional Ethics Committee. Mr. Shanley currently serves on the Board of Harris & Harris Group, Inc. He earned his B.S. degree from Fordham University
and his M.B.A. in Accounting from Long Island University.(4)Robert Chefitzhas been a General Partner of NJTC Venture Fund, SBIC, L.P., a private venture capital
firm based in New Jersey that is a lead investor in seed and early stage companies in the region since April 2002. Prior to joining the NJTC Venture Fund, from February 1987 to October 2001,
Mr. Chefitz was a partner at Apax Partners based in New York. Prior to Apax Partners, Mr. Chefitz was employed as an investment professional with Golder Thoma Cressey in Chicago.
Mr. Chefitz is a past president of the New York Venture Association. Mr. Chefitz holds a B.A. in History from Northwestern University and a M.B.A. from Columbia University. In addition
to Redpoint, Mr. Chefitz serves as a director on the boards at Hycrete Technologies, LLC, Achieve 3000, Point Blank Solutions, Inc., Westec Intelligent Surveillance, Alarm.com,
The Ladders.com, and RightAnswers, Inc. Mr. Chefitz has been a director of Original Redpoint since 2003.(5)Leif Kjaergaard, Ph.D., is currently the President of Leif and Food Science, a consulting firm to the food
industry. Prior to that he was the Chief Technology Officer and a member of the executive committee at Danisco A/S, an international food ingredients and biotechnology company based in Denmark from
2006 to 2008. Dr. Kjaergaard was responsible for new technology ventures and business development throughout Danisco. From 2002 to 2006, Dr. Kjaergaard was Senior Vice President of
Danisco, and, from 1993 to 2002, he served as Executive Vice President and Department President of Danisco Cultor (formerly Danisco Ingredients). Dr. Kjaergaard has a


4

---



Table of Contents

M.Sc.
in Chemical Engineering and a Ph.D. in Biotechnology from the Technical University of Denmark. Dr. Kjaergaard is a member of the European Research Advisory Board, past President of the
Board of European Industrial Research Managers Association, and deputy chair of the Advisory Council on Research Policy in Denmark. He also serves as deputy chairman of the independent company BHJ in
Denmark, and a member of the board of the Danish Investment Fund (Dansk Innovationsinvestering), a board member of Direvo Biotech (Germany) and a senior advisor to the American Investment bank
AgriCapital Inc. Dr. Kjaergaard has been a director of Original Redpoint since 2006. (6)Allen Bloom, Ph.D.was appointed as a director on September 12, 2007. From 1994 until 2003,
Dr. Bloom, a patent attorney, was a partner at the law firm of Dechert LLP, where he served as Co-Chair of the Intellectual Property Group and headed a patent practice group
focusing on biotechnology, pharmaceuticals and medical devices. From 1985 until mid-1994, Dr. Bloom was Vice President, General Counsel and Secretary of The Liposome
Company, Inc., where he managed patent, regulatory and licensing activities. Before that, Dr. Bloom served as Patent Attorney and Patent Counsel for Pfizer, Inc. and RCA
Corporation, respectively. Dr. Bloom currently serves on the Board of the biopharmaceutical company Unigene Laboratories, Inc., where he is lead director. He earned his Ph.D. in organic
chemistry from Iowa State University, a J.D. degree from New York Law School and a B.S. in Chemistry from Brooklyn College.(7)Irwin Scher, M.D.was appointed as a director on September 12, 2007. Since 2005, Dr. Scher has
held the position of President and Chief Executive Officer of Biosynexus, a biotechnology company focused on treating and preventing Staphylococcal infections. Prior to joining Biosynexus,
Dr. Scher spent 22 years in various positions at Merck, Astra/Merck, Astra Zeneca and until 2005 as Consultant to the Chief Executive Officer at Merck KGaA. Before joining Merck,
Dr. Scher enjoyed a long career in academic medicine. He held the rank of Captain USN Medical Corps and was stationed for 12 years at the Bethesda Naval Medical Complex. While there,
Dr. Scher served as Professor of Medicine, Uniformed Services University, and Head, Immunology Branch, Naval Medical Research Institute. Dr. Scher is certified by the American Board of
Rheumatology and American Board of Internal Medicine. He received his M.D. from Albert Einstein College of Medicine in New York and completed residencies at Presbyterian Hospital, University of
Pittsburgh Medical Center, and Albert Einstein College of Medicine. Dr. Scher holds a B.S. in Chemistry from the State University of New York at Albany.


None
of our executive officers is related to any other executive officer or to any of our Directors. Our executive officers are elected annually by the Board of Directors and serve until
their successors are duly elected and qualified.

Committees of the Board of Directors and Director Independence

Our Board currently has four standing committees: an Audit Committee, a Compensation Committee, a Nominating and Governance Committee
and an Intellectual Property Oversight Committee. These committees, their principal functions and their respective memberships are described below.



The current members of the Audit Committee are Mr. Shanley, who serves as Chairman, Dr. Bloom and Mr. Chefitz.
Each of the members of the Audit Committee is independent as defined by the applicable NASDAQ listing standards and Securities and Exchange Commission ("SEC") rules applicable to audit committee
members. Our Board has determined that Mr. Shanley also qualifies as an audit committee financial expert as defined by the SEC.

5

---



Table of Contents

The
Audit Committee oversees our financial reporting process and system of internal control over financial reporting, and selects and oversees the performance of, and approves in advance
the services provided by, our independent registered public accounting firm. The Audit Committee provides an open avenue of communication among our independent registered public accounting firm,
financial and senior management and the Board. The Audit Committee meets regularly with our independent registered public accounting firm without management present, and from time to time with
management in separate private sessions, to discuss any matters that the Committee or these individuals believe should be discussed privately with the Audit Committee, including any significant issues
or disagreements that may arise concerning our accounting practices or financial statements. The Audit Committee also oversees our whistleblower policy for receiving and handling complaints or
concerns regarding accounting, internal accounting controls or auditing matters. In addition, the Audit Committee assists the Board in its oversight role by receiving periodic reports regarding our
risk and control environment.

The
Audit Committee held 5 meetings during the year ended December 31, 2010.



The current members of the Nominating and Governance Committee (the "Governance Committee") are Mr. Kjaergaard, who serves as
Chairman, Dr. Scher and Mr. Shanley. Each of the members of the Governance Committee is independent as defined by the applicable NASDAQ listing standards.

The
Governance Committee assists the Board in fulfilling its responsibilities regarding the oversight of the composition of the Board and other corporate governance matters. Among its
other duties, the Governance Committee evaluates nominees and reviews the qualifications of individuals eligible to stand for election and reelection as directors and makes recommendations to the
Board on this matter; oversees compliance with our Code of Business Conduct; reviews and approves related party transactions; recommends and advises the Board on certain other corporate governance
matters; and oversees the Board's performance evaluation process. The Governance Committee does not have a specific policy with regard to the consideration of diversity in identifying director
nominees. However, our Governance Committee values diversity on our Board and considers the diversity of the professional experience, education and skills, as well as diversity of origin, in
identifying director nominees.

The
Governance Committee held 1 meeting during the year ended December 31, 2010. A copy of the Governance Committee's charter is posted on our website at www.redpointbio.com.



The current members of the Intellectual Property Oversight Committee (the "IP Committee") are Dr. Bloom, who serves as Chairman
and Dr. Scher. Each of the members of the IP Committee is independent as defined by the applicable NASDAQ listing standards.

The
IP Committee assists the Board in evaluating the Company's strategic business decisions and reviewing the Company's strategy and policy with respect to the development and protection
of its intellectual property. Among its other duties, the IP Committee provides oversight of the Company's management of those activities.

The
IP Committee held 1 meeting during the year ended December 31, 2010. A copy of the IP Committee's charter is posted on our website at www.redpointbio.com.

6

---



Table of Contents



The current members of the Compensation Committee are Dr. Bloom, Mr. Chefitz and Dr. Kjaergaard.
Mr. Chefitz serves as Chairman of the Compensation Committee. Each of the current members of the Compensation Committee is independent as defined by the applicable NASDAQ listing standards.

Decisions
regarding the compensation of our executive officers are made by the Compensation Committee. The Compensation Committee's principal responsibilities include reviewing
Redpoint's overall compensation philosophy and the adequacy and market competitiveness of our compensation plans and programs, evaluating the performance of and reviewing and approving compensation
for our executive officers, evaluating and recommending director compensation, and reviewing and discussing with management the Compensation Discussion and Analysis included in this annual report on
Form 10-K. The Compensation Committee also administers our equity-based and other incentive plans, including assuming responsibility for granting, or delegating as appropriate the
authority for granting, and making decisions with respect to, awards under our equity compensation and other incentive plans.

To
assist the Compensation Committee in its efforts to meet the objectives and responsibilities outlined above, management has retained an executive compensation consulting firm. During
2010, the Company retained Strategic Outsourcing Solutions LLC, a compensation consulting firm that works with a number of local life science companies, to advise the Compensation Committee on
various matters related to executive compensation and compensation programs. For additional information on the projects undertaken by these consultants, see the discussion under "Compensation
Discussion and Analysis" included in this annual report on Form 10-K. The consultants were engaged to provide general executive compensation consulting services and to respond to
questions as needed. In addition, the consultants perform special executive compensation projects and consulting services from time to time as directed by the Compensation Committee and may from time
to time advise management, with the Compensation Committee's consent. The consultants were hired by management and report to the Compensation Committee. Pursuant to its charter, the Committee has the
power to hire and fire such consultants and to engage other advisors. The human resources consultant retained by management also provides information and support to the Compensation Committee as
requested.

The
Compensation Committee held 1 meeting during the year ended December 31, 2010. A copy of the Compensation Committee's charter is posted on our website at www.redpointbio.com.

Under
NASDAQ rules, a Director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship which would interfere
with the exercise of independent judgment in carrying out the responsibilities of a Director. Our Board of Directors has determined that with the exception of Dr. Salemme, who serves as our
President and Chief Executive Officer, none of our directors has a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a Director and
that each of
these Directors is an "independent director" as defined under Rule 5605(a)(2) of the NASDAQ Stock Market Marketplace Rules.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") requires our directors and executive officers and
persons who own more than 10% of our outstanding shares of common stock to file with the SEC initial reports of ownership and reports of changes in ownership in our common stock and other equity
securities. Specific due dates for these records have been established, and we are required to report in this annual report on Form 10-K any failure in 2009 to file by these dates.
To our knowledge, based solely on a review of the copies of such reports furnished to us and representations that no other reports were required, there were no reports required under

7

---



Table of Contents

Section 16(a)
of the Exchange Act that were not timely filed during the fiscal year ended December 31, 2009.

Code of Ethics

We have adopted a written code of conduct that applies to all of our employees, including our principal executive officer, principal
financial officer and principal accounting officer, or persons performing similar functions. We make available our code of conduct free of charge through our web site which is located at www.redpointbio.com. We intend to disclose any amendments to, or waivers from, our code of conduct that are required to be publicly disclosed pursuant
to rules of the SEC and NASDAQ by filing such amendment or waiver with the SEC and by posting it on our web site.

ITEM 11.    EXECUTIVE COMPENSATION.

Compensation of Directors

Discussed in the following paragraphs and tables is the compensation paid to the non-employee directors who serve on our
Board. Directors who are also our employees do not receive any additional compensation for their service as directors of the Company.

During
our 2010 fiscal year, directors who were employees did not receive any cash remuneration for serving as directors. We reimbursed each non-employee member of our Board
for out-of-pocket expenses incurred in connection with attending our Board and Committee meetings. We also paid each of our non-employee directors a fee for each
Board and Committee meeting attended, of $1,500 for each Board meeting attended in person and $750 for Board meetings attended by telephone, and $1,000 for each Committee meeting attended in person
and $500 for Committee meetings attended by telephone. Each of our non-employee directors received an annual retainer of $17,500 for service as a director and the Chairman of our Board
received an annual retainer of $20,000, both paid quarterly and pro-rated for the period of time such person held the position during 2010. The Chairman of our Audit Committee received an
additional annual retainer of $10,000; other committee chairmen received an additional annual retainer of $5,000.

In
order to conserve cash, on April 1, 2011, each of our directors agreed to indefinitely defer all cash remuneration for serving as directors, at least until the Company has
raised additional capital. The cash remuneration due to the directors is being accrued for by the Company.

Additionally,
under the non-employee director compensation program in place during 2010, if a non-employee Board member had joined our Board in 2010, such
non-employee Board member would have received an annual option grant to purchase 25,000 shares of common stock for their service as a director, granted on or before the date of the initial
Board meeting appointing such director to serve on our Board and fully vesting on the first anniversary of the grant date, subject to the director's continued service as a director.

The
following table further summarizes the compensation paid by us to our non-employee directors during the 2010 fiscal year. Except as noted below, all of our directors are
paid at the same rate. The differences among directors in the table below are a function of dates of service on the Board

8

---



Table of Contents

during
the year, additional compensation for chairing a committee and varying numbers of meetings attended during 2010 and corresponding payments of meeting fees.

Name(1)
(a)

Fees Earned
or Paid
in Cash
($)(2)
(b)

Stock
Awards
($)
(c)

Option
Awards
($)(3)(4)
(d)

Non-Equity
Incentive Plan
Compensation
($)
(e)

Change in
Pension
Value and
Nonqualified
Deferred
Compensation
Earnings
($)
(f)

All Other
Compensation
($)
(g)

Total
($)
(h)Joseph Mollica, Ph.D(5).

$
1,096




$











$
1,096Robert Chefitz(6)




















Leif Kjaergaard, Ph.D.

$
61,493




$
2,614










$
64,107Allen Bloom, Ph.D.

$
34,750




$
2,614










$
37,364Irwin Scher, M.D.

$
27,459




$
2,614










$
30,073Richard P. Shanley, CPA

$
42,583




$
2,614










$
45,197


(1)Dr. Raymond
F. Salemme, our President and Chief Executive Officer, is not included in this table as he is an employee of Redpoint and thus receives
no compensation for his services as a director. The compensation received by Dr. Salemme is shown in the Summary Compensation Table and other executive compensation tables included in this
annual report on Form 10-K.(2)Consists
of amounts described under "Compensation of our Directors2010 Compensation."(3)The
amounts included in this column are the dollar amounts representing the full grant date fair value of each option award calculated in accordance with
the Financial Accounting Standards Board Accounting Standards Codification Topic 718, "Compensation-Stock compensation," or FASB ASC Topic 718, and do not represent the actual value that may be
recognized by the director upon option exercise. For information on the valuation assumptions used in calculating this amount, see Note 12 to Redpoint's audited financial statements included in
the Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC.(4)The
aggregate grant date fair value of the stock options granted to the directors in 2010 in accordance with FASB ASC Topic 718 was $0.07. The following
table lists the number of outstanding options held by each of the directors included in the table above as of December 31, 2010, and provides additional information concerning the options
granted to these directors during 2010, each of which fully vests on the first anniversary of the grant date and was granted at an exercise price equal to the closing price of Redpoint's common stock
as reported by the OTC Bulletin Board on the respective date of grant.(5)Dr. Mollica
resigned as a member and Chairman of our Board on January 8, 2010.(6)Such
director waived any and all fees associated with being a director.


Options
Outstanding
as of
December 31,
2010
(#)

Options
Granted
in 2010
Fiscal
Year
(#)

Date of
2010
Option
Grant

2010
Option
Expiration
Date

2010
Option
Exercise
Price
($/Sh)

Grant Date
Fair Value of
Option
Awards
Granted in
2010 ($)Joseph Mollica, Ph.D.(1)

















Allen Bloom, Ph.D.


125,000


25,000


6/3/2010


6/3/2020

$
0.17

$
2,614Irwin Scher, M.D.


125,000


25,000


6/3/2010


6/3/2020

$
0.17

$
2,614Leif Kjaergaard, Ph.D.


50,000


25,000


6/3/2010


6/3/2020

$
0.17

$
2,614Richard P. Shanley, CPA


125,000


25,000


6/3/2010


6/3/2020

$
0.17

$
2,614


9

---



Table of Contents

Compensation Discussion and Analysis

Overview

This Compensation Discussion and Analysis discusses the principles underlying our compensation policies and decisions and the principal
elements of compensation paid to our named executive officers during the 2010 fiscal year. Our named executive officers include our Chief Executive Officer, F. Raymond Salemme, Ph.D., or CEO,
and Chief Financial Officer, Scott M. Horvitz, or CFO.

Our
executive compensation program is designed to provide performance-oriented incentives that fairly compensate our executive officers and enable us to attract, motivate and retain
highly qualified executives and scientific, development and commercial personnel. Our compensation program consists of both short-term and long-term components, including cash
and equity-based compensation, and is intended to reward consistent performance that meets or exceeds formally established strategic business and scientific goals and objectives that enhance
stockholder value. The Compensation Committee of the Board of Directors, referred to herein as the Committee, and senior management is focused on providing an appropriate mix of short-term
and long-term incentives to ensure that our executives continue in employment with us and generate stockholder value. We are mindful not to rely on highly leveraged incentives that would
result in risky short-term behavior.

Our
continued research and development efforts have led us to certain advances within our taste technology platform, including the identification of RP44, an all-natural
sweetness enhancer, which we licensed to IFF in June of 2010. However, we recognize the difficult financing environment that has hit the biotechnology sector particularly hard which has required the
Company to seek ways to conserve cash.

On
March 29, 2011, the Committee met to review the Company's performance for 2010. Taking all of the above factors into consideration, the Committee determined not to award a
2010 year end bonus or provide new option grants to its executive officers, and it did not provide any increase in salary to its executive officers. In addition, in order to conserve cash, on
March 1, 2011, each of our executive officers agreed to indefinitely defer one-third of the cash portions of their salaries, at least until the Company has raised additional capital
or the compensation committee of the board of directors determines otherwise. The cash amounts due to the executive officers are being accrued for by the Company.

Compensation Objectives and Philosophy

The Committee oversees and administers our executive compensation program, including the evaluation and approval of compensation plans,
policies and programs offered to our named executive officers. As part of such process, the Committee seeks to accomplish the following objectives with respect to our executive compensation
program:



The
Committee seeks to achieve these objectives by:



10

---





Table of Contents

Setting Executive Compensation

It is the Committee's objective to set the total annual compensation of each executive officer at levels that are competitive for
comparable positions based on available industry data. However, in determining the compensation of each executive officer, the Committee also considers a number of other factors, including recent
corporate and individual performance, the CEO's recommendations, cost of living and internal pay equity. There is no pre-established policy for allocation of compensation between cash and
non-cash components or between short-term and long-term components. Instead, the Committee determines the mix of compensation for each executive officer based on
its review of the competitive data and its subjective analysis of that individual executive's performance and contribution to the our overall performance. In addition, the CEO provides the Committee
with a detailed review of the performance of the other named executive officers and makes recommendations to the Committee with respect to the compensation packages for those officers.

The
relative difference between the annual compensation package provided to our CEO in the form of base salary, short-term incentive compensation and long-term
equity awards and the comparable compensation packages provided to our other named executive officers has not increased significantly since his hiring in June 2004 and which we believe is a fair and
equitable allocation among all our named executive officers.

For
purposes of measuring the competitive levels of the cash elements of our officer compensation package for the 2010 fiscal year, the Committee relied on the 2010 Radford Global Life
Sciences Survey Report, referred to herein as the Radford Survey, generally benchmarking companies with less than 50 employees, as its primary source of market data. The Committee is committed to the
ongoing evaluation of our compensation program through surveys, analysis and best practices within the biotechnology industry.

Components of Compensation

We have structured our company-wide employee compensation program to attract, develop, motivate and retain top talent and
to focus our employees, including our named executive officers, on key business goals that enhance stockholder value. We use compensation as a means to reinforce our desired culture and unique
corporate environment. The following principal components of 2010 compensation that we provided to our named executive officers were designed to meet the objectives of our executive compensation
program discussed above:



It
is important to note that we do not have any non-qualified deferred compensation programs, pension plans or supplemental executive retirement plans for our named executive
officers; however, in order to conserve cash, on March 1, 2011, each of our executive officers agreed to indefinitely defer one-third of the cash portions of their salaries, at
least until the Company has raised additional capital or the compensation committee of the board of directors determines otherwise. The cash amounts due to the executive officers are being accrued for
by the Company. The only deferral program that allows our named executive officers to accumulate a retirement income source is our 401(k) savings plan, which is subject to dollar limitations imposed
under the Internal Revenue Code and its corresponding regulations on the maximum amount an individual can contribute each year. As a result, the equity incentive awards provided to our named executive
officers are intended to serve as the primary source

11

---



Table of Contents

of
wealth-accumulation for our named executive officers while at the same time incentivizing them to contribute to our financial success as measured in terms of appreciation in the value of our common
stock.

The
Committee reviews our compensation program periodically, including each of the above elements, to determine whether they provide appropriate incentives and motivation to our named
executive officers and whether they adequately compensate our named executive officers relative to comparable officers in other companies with which we compete for executives. Based upon the
information and data presented to it, the Committee generally views the compensation paid to our named executive officers as fair, reasonable and competitive.

We
believe our approach to goal setting assists in mitigating excessive risk-taking that could harm our value or reward poor judgment by our executives. Several features of
our programs reflect sound risk management practices. We believe we have allocated our compensation among base salary and short and long-term compensation target opportunities in such a
way as to not encourage excessive risk-taking. In addition, under our equity compensation plan we may provide a mix of equity award instruments that includes full value awards as well as
the multi-year vesting of our equity awards, which will also mitigate risk and properly account for the time horizon of risk.

Base Salary

In GeneralIt is the Committee's objective to set a competitive rate of annual base salary for each executive officer. The Committee believes
competitive base salaries are necessary to attract and retain top quality executives, since it is common practice for companies to provide their executive officers with a guaranteed annual component
of compensation that is not subject to performance risk. The Committee works with the Company's CFO to establish salary bands for the executive officers, with minimum to maximum opportunities that
cover the normal range of market variability. The actual base salary for each executive officer is then derived from those salary bands based on his or her responsibility, tenure, past performance and
market comparability.

Changes for Fiscal Year 2010On March 29, 2010, the Committee met to review performance for 2009. During 2009, our continued research and
development efforts had led us to certain advances within our taste technology platform, including our announcement concerning the identification of RP44, an all-natural sweetness
enhancer. However, during 2009, we did not enter into any new funded corporate collaborations. We were also unable to renew our one year agreement with The Coca-Cola Company and the
agreement our agreement with Givaudan was terminated by Givaudan on May 1, 2009. Furthermore, we recognized the difficult financing environment that has hit the biotechnology sector
particularly hard which required the Company to seek ways to conserve cash. Consequently, the Committee determined not to provide an increase in salary to its named executive officers for 2010. The
base salaries for our named executive officers during 2010 are set forth in the table below.

Name

Title

2010
Salary

% IncreaseDr. F. Raymond Salemme

Chief Executive Officer and President

$
350,625


0.00
%Scott M. Horvitz

Chief Financial Officer, Treasurer and Secretary

$
251,805


0.00
%


Changes for Fiscal Year 2011On March 29, 2011, the Committee met to review performance for 2010. Our continued research and development
efforts have led us to certain advances within our taste technology platform, including the identification of RP44, an all-natural sweetness enhancer, which we licensed to IFF in June of
2010. However, we recognize the continuing difficult financing environment that has hit the biotechnology sector particularly hard which has required the Company to seek ways to conserve cash.
Consequently, the Committee determined not to provide an increase in salary to its

12

---



Table of Contents

named
executive officers for 2011. In addition, in order to conserve cash, on March 1, 2011, each of our executive officers agreed to indefinitely defer one-third of the cash
portions of their salaries, at least until the Company has raised additional capital or the compensation committee of the board of directors determines otherwise. The cash amounts due to the executive
officers are being accrued for by the Company.

The
2011 base salaries for our named executive officers are set forth in the table below.

Name

Title

2011
Salary

% IncreaseDr. F. Raymond Salemme

Chief Executive Officer and President

$
350,625


0.00
%Scott M. Horvitz

Chief Financial Officer, Treasurer and Secretary

$
251,805


0.00
%


Annual Bonuses

In GeneralAs part of their compensation package, our executive officers have the opportunity to earn annual cash incentive awards under our cash
bonus program. The bonus program is designed to reward superior executive performance while reinforcing our short-term strategic operating goals. The target awards, based on percentage of
base salary were determined at the time the executive was hired. Annual bonus targets as a percentage of salary generally increase with executive rank so that for the more senior executives, a greater
proportion of their total cash
compensation is contingent upon annual performance. All of our employees are eligible to participate in our cash bonus program.

Fiscal 2010 Performance Measures and PayoutsTarget awards for 2010 ranged from 25% to 40% of base salary for the executive officers and are payable
based on the Committee's subjective review of both corporate and individual performance and the achievement of corporate and individual goals. The target bonus for the CEO is allocated 90% for
corporate goals and 10% for individual performance. For the other named executive officers, the target bonus is allocated 80% for corporate goals and 20% for individual performance.

When
assessing corporate performance, the Committee reviews how we did overall in achieving our key objectives, varying from year to year, but including financial goals, corporate
development and scientific progress. Each factor is given a weight in proportion to the relative level of importance as determined by the Board. As previously mentioned, our continued research and
development efforts have led us to certain advances within our taste technology platform, including the identification of RP44, an all-natural sweetness enhancer, which we licensed to IFF
in June of 2010. However, the Committee also recognized the difficult financing environment that has hit the biotechnology sector particularly hard which required the Company to seek ways to conserve
cash. Consequently, the Committee determined not to provide a 2010 bonus to its named executive officers.

The
table below details fiscal 2010 annual bonus targets and actual bonus amounts.

Name

Title

2010
Target
Bonus
($)

2010
Target
Bonus
(% Salary)

2010
Actual
Bonus
($)

2010
Actual
Bonus
(% Salary)Dr. F. Raymond Salemme

Chief Executive Officer and President

$
140,250


40
%




0
%Scott M. Horvitz

Chief Financial Officer, Treasurer and Secretary

$
75,542


30
%




0
%


13

---



Table of Contents

Long-Term Incentive Equity Awards

A significant portion of each named executive officer's compensation is provided in the form of long-term incentive equity
awards. The Committee believes that properly structured equity awards are an effective method for aligning the long term interests of our named executive officers with those of our stockholders. All
of our employees are eligible to receive long-term incentive awards.

We
provide our named executive officers with long-term incentive equity awards through our Amended and Restated 2007 Omnibus Equity Compensation Plan (the "Equity Plan"),
which was approved by our stockholders on March 12, 2007. The Equity Plan is intended to provide us with the means to attract and retain the services of individuals who are essential to our
growth and profitability and align the economic interests of those individuals with those of our stockholders. The Equity Plan authorizes us to grant incentive stock options, nonqualified stock
options, stock appreciation rights, stock awards, stock units and other stock-based awards. To date, we have only granted stock options under the Equity Plan.

All
stock options granted to our employees and directors were granted with an exercise price that was no less than the fair market value of a share of our common stock on the date such
options were granted. All option grants granted in 2009 typically vested over four years, with one quarter of the shares subject to the stock option vesting on the one year anniversary of the grant
date and the remaining shares vesting at the rate of 1/48 of the original grant amount each month thereafter for three years. The Committee determined that this vesting schedule
achieves our goal of encouraging the retention and dedication of participants to our growth and success over a long time horizon. All options have a ten year term. Additional information regarding
accelerated vesting upon termination of employment or in connection with a change of control is discussed below under "Potential Payments on Termination Or Change of Control."

We
generally make grants at the beginning of the fiscal year, based on Company and individual performance in the prior fiscal year and also upon hiring. As previously mentioned, our
continued research and development efforts have led us to certain advances within our taste technology platform, including the identification of RP44, an all-natural sweetness enhancer,
which we licensed to IFF in June of 2010. In recognition of this achievement, in 2010, the Committee granted stock options under the Equity Plan to our named executive officers as follows:

Name

Title

Option grant August 19, 2010Dr. F. Raymond Salemme

Chief Executive Officer and President


300,000Scott M. Horvitz

Chief Financial Officer, Treasurer and Secretary


200,000


Retirement and Health Insurance Benefits



Our named executive officers are eligible to participate in our tax-qualified 401(k) defined contribution plan. The plan is
available to all eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited by the maximum amounts allowable under the Internal Revenue Code and its
corresponding regulations. The Company offers a matching contribution of 50% of employee contributions up to 6%. The Company, in its discretion, may also make certain other contributions.

Other Benefits and PerquisitesAll employees, including our named executive officers, are eligible to receive standard health, disability and life
insurance benefits.

14

---



Table of Contents

Change of Control and Other Severance Agreements

The offer letters for each of our named executive officers provide for payments in the event that the executive is terminated by us
without cause or by the executive for good reason.

If
the executive's employment is terminated by us without cause or by the executive for good reason, all of the executive's outstanding stock options that would have vested in the
12 month period following the termination of his employment will immediately accelerate and become fully vested. In addition, all of the executive's outstanding stock options will accelerate
and become fully vested upon a change of control, without regard to a termination of employment.

See
"Potential Payments on Termination and Change of Control" appearing on page 18 of this annual report on Form 10-K for further information regarding the
severance and change of control payments and benefits under the offer letters.

IRC Section 162(m) compliance

As a result of Section 162(m) of the Internal Revenue Code, publicly traded companies such as us are not allowed a federal
income tax deduction for compensation, paid to its CEO and the next three most highly-compensated executive officers (except our CFO), to the extent that such compensation exceeds $1 million
per officer in any one year and does not otherwise qualify as performance-based compensation. The Equity Plan is structured so that compensation deemed paid to an executive officer in connection with
the exercise of a stock option should qualify as performance-based compensation that is not subject to the $1 million limitation. Other awards made under the Equity Plan may or may not so
qualify. In establishing the cash and equity incentive compensation programs for the executive officers, it is the Committee's view that the potential deductibility of the compensation payable under
those programs should be only one of a number of
relevant factors taken into consideration, and not the sole governing factor. For that reason the Committee may deem it appropriate to continue to provide one or more executive officers with the
opportunity to earn incentive compensation, including cash bonus programs tied to the Company's financial performance and restricted stock unit awards, which may be in excess of the amount deductible
by reason of Section 162(m) or other provisions of the Internal Revenue Code. It is the Committee's belief that cash and equity incentive compensation must be maintained at the requisite level
to attract and retain the executive officers essential to the Company's financial success, even if all or part of that compensation may not be deductible by reason of the Section 162(m)
limitation. However, for the 2010 fiscal year, the total amount of compensation paid by the Company (whether in the form of cash payments or upon the exercise or vesting of equity awards) should be
deductible and not affected by the Section 162(m) limitation.

Summary Compensation Table

The following 2010 Summary Compensation Table provides certain information concerning the compensation earned for services rendered in
all capacities to us for the year ended December 31, 2010 for our named executive officers. No other executive officers who would have otherwise been

15

---



Table of Contents

includable
in such table on the basis of total compensation for the 2010 fiscal year have been excluded by reason of their termination of employment or change in executive status during that year.

Name and Principal Position
(a)

Year
(b)

Salary($)
(c)

Bonus($)
(d)

Stock
Awards
($)
(e)

Option
Awards(1)
($)
(f)

Non-Equity
Incentive Plan
Compensation
($)
(g)

Nonqualified
Deferred
Compensation
Earnings ($)
(h)

All Other
Compensation(2)
($)
(i)

Total ($)
(j)F. Raymond Salemme, Ph.D.


2010

$
350,625







$
20,469







$
7,350

$
378,444President and Chief


2009

$
350,625
















$
7,350

$
357,975Executive Officer


2008

$
350,625







$
312,362







$
6,900

$
669,887Scott M. Horvitz


2010

$
251,805







$
13,646







$
7,350

$
272,801Chief Financial Officer,


2009

$
251,805
















$
7,350

$
259,155Treasurer and Secretary


2008

$
251,805







$
104,121







$
6,900

$
362,826


(1)The
amounts included in this column are the dollar amounts representing the full grant date fair value of each option award calculated in accordance with
the Financial Accounting Standards Board Accounting Standards Codification Topic 718, "Compensation-Stock compensation," or FASB ASC Topic 718, and do not represent the actual value that may be
recognized by the named executive officer upon option exercise. For information on the valuation assumptions used in calculating this amount, see Note 12 to Redpoint's audited financial
statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as filed with the SEC.(2)For
each named executive officer, the amounts shown in this column represent an employer matching contribution to a 401(k) plan.


Grants of Plan-Based Awards

The following table provides additional information about awards granted to our named executive officers in 2010.

All Other
Stock
Awards:
Number of
Shares
of Stock
or Units
(#)
(i)

All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)
(j)



Grant
Date Fair
Value of
Stock
and
Option
Awards
($)(1)
(l)Potential Future Payouts
Under Non-Equity Incentive
Plan Awards(1)

Estimated Future Payouts
Under Equity Incentive Plan
Awards

Exercise
or Base
Price of
Option
Awards
$/Sh)
(k)Name
(a)

Grant
Date
(b)

Threshold
($)
(c)

Target
($)
(d)

Maximum
($)
(e)

Threshold
(#)
(f)

Target
(#)
(g)

Maximum
(#)
(h)F. Raymond Salemme, Ph.D.


8/19/10























300,000

$
0.11

$
20,469Scott M. Horvitz


8/19/10























200,000

$
0.11

$
13,646


(1)Represents
the grant date fair value under FASB ASC Topic 718 of stock options awarded in 2010. For information regarding assumptions underlying the FASB
ASC Topic 718 valuation of equity awards, see Note 12 of the Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31,
2010, as filed with the Securities and Exchange Commission.


16

---



Table of Contents




Outstanding Equity Awards as of December 31, 2010

The following table summarizes the equity awards we have made to our named executive officers that have not been exercised and remained
outstanding as of December 31, 2010.

Option Awards(1)

Stock AwardsName
(a)

Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
(b)

Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
(c)

Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
(d)

Option
Exercise
Price
($)
(e)

Option
Expiration
Date
(f)

Number of
Shares or
Units
of Stock
That
Have
Not
Vested
(#)
(g)

Market
Value of
Shares or
Units of
Stock
That
Have
Not
Vested
($)
(h)

Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have
Not
Vested
(#)
(i)

Equity
Incentive
Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)
(j)F. Raymond Salemme, Ph.D.


1,629,142







$
0.15


11/3/20142,132,021


142,135




$
0.81


3/12/2017546,875


203,125




$
0.66


1/31/2018300,000




$
0.11


8/19/2020Scott M. Horvitz


58,823







$
0.15


12/17/201335,498







$
0.15


5/26/2014379,786







$
0.15


11/3/201453,937







$
0.15


11/3/2014710,670


47,378




$
0.81


3/12/2017182,291


67,709




$
0.66


1/31/2018200,000




$
0.11


8/19/2020


(1)Each
stock option grant included in this table that is not fully vested, has a term of 10 years measured from the grant date and vests 25% on the
first anniversary of the grant date and 1/48th on a monthly basis thereafter, until all such options are vested on the fourth anniversary of the grant date.


Option Exercises and Stock Vested in 2010 Fiscal Year

The table disclosing option exercises and the vesting of stock awards during the year is omitted because none of our named executive
officers exercised any stock options or had any stock awards vest.

Pension Benefits for 2010 Fiscal Year

The table disclosing the value of accumulated benefits under and other information concerning defined benefit plans during the year is
omitted because we do not have a defined benefit plan for our named executive officers or other employees. The only retirement plan available to our named executive officers in 2010 was our 401(k)
plan which is available to all employees.

Nonqualified Deferred Compensation for 2010 Fiscal Year

The table disclosing contributions to and aggregate earnings under or distributions from nonqualified defined contribution or other
deferred compensation plans is omitted because we do not have any such nonqualified deferred compensation plans.

17

---





Table of Contents

Potential Payments on Termination and Change of Control

The offer letters for each of our named executive officers provide each officer with certain payments and benefits upon termination of
employment in certain circumstances and in connection with a change of control. This section describes these payments and benefits, with amounts based on the assumption that a named executive
officer's termination of employment with us occurred on December 31, 2010. The information in this section does not include information relating to payments and benefits provided on a
nondiscriminatory basis to salaried employees generally upon termination of employment. On December 31, 2010, the last reported sale price of our common stock on the OTC Bulletin Board was
$0.13 per share. Actual amounts payable would vary based on the date of the named executive officer's termination of employment and can only be finally determined at that time.

Unless
specified otherwise, the information in this section is based upon the terms of the (i) Offer Letter between us and F. Raymond Salemme, dated as of May 25, 2004, and
amended on December 19, 2008 ("Dr. Salemme's Letter"); and (ii) Offer Letter between us and Scott M. Horvitz, dated as of June 28, 2004, and amended on December 19,
2008 ("Mr. Horvitz's Letter"). Dr. Salemme's Letter and Mr. Horvitz's Letter are collectively referred to in this section as the "Offer Letters."



The Offer Letters provide each of our named executive officers severance payments and benefits upon termination of their employment by
us without cause. We will continue each of our named executive officers' respective base salaries (as in effect at the time of their termination of employment) for twelve months. We will also continue
health and dental benefits for a period of twelve months for them and, where applicable, their spouses and dependents. Furthermore, each of the named executive officers will receive an additional
twelve months of vesting following the date of their termination of employment with respect to their outstanding stock options. Furthermore, each of the named executive officers will receive an
additional twelve months of vesting following the date of their termination of employment with respect to their then-outstanding stock options.



The Offer Letters for Dr. Salemme and Mr. Horvitz provide Dr. Salemme and Mr. Horvitz with severance
payments and benefits upon their resignation for good reason. While Dr. Salemme may resign for good reason either before or after a change of control, Mr. Horvitz may resign for good
reason only after a change of control. If Dr. Salemme and Mr. Horvitz resign for good reason, they will be entitled to the same payments and benefits that they would receive had their
employment been terminated by us without cause. Dr. Salemme and Mr. Horvitz will have good reason to resign if there is: (i) a material diminution in their responsibilities,
duties or authority as provided in their respective Offer Letters; (ii) a material diminution in their base compensation without their consent; (iii) a relocation of our executive
offices or their principal place of employment by more than forty miles from its current location without their consent; or (iv) any other action or inaction that constitutes a material breach
by us of any provision of their Offer Letters.



The Offer Letters do not provide our named executive officers with any payments or other benefits in the event of their termination of
employment by us for cause, for Dr. Salemme and Mr. Horvitz only, their resignation without good reason. A termination for cause under the Offer Letters generally would result from an
executive's: (i) engagement in intentional misconduct that materially harms us, (ii) conviction of a felony, (iii) act of fraud against us or willful material misappropriation of
our property, (iv) material breach of the confidentiality, nondisclosure, noncompetition and invention

18

---



Table of Contents

assignment
agreement between the executive and us, and (v) willful disregard of the executive's material duties despite adequate warnings from the Board.



Upon a change of control, the Offer Letters provide that all outstanding stock options held by our named executive officers will become
fully vested, without regard to a termination of employment. A change of control includes (i) the acquisition of our company by merger, (ii) the sale of all or substantially all of our
assets, (iii) the purchase of fifty percent or more of our voting securities, or (iv) any other reorganization resulting in a change of fifty percent or more in the ownership of our
outstanding voting securities.

The
following table summarizes the amounts payable to each of our named executive officers based on the items described above with respect to each of the events set forth in the table.

Without
Cause

Good
Reason

Upon
Change of
ControlF. Raymond Salemme, Ph.D.Salary Continuation

$
350,625

$
350,625


Benefits Continuation

$
31,139

$
31,139


Option Acceleration(1)

$
2,000

$
2,000

$
2,000Total

$
383,764

$
383,764

$
2,000Scott M. HorvitzSalary Continuation

$
251,805

$
251,805


Benefits Continuation

$
31,139

$
31,139


Option Acceleration(1)

$
1,333

$
1,333

$
1,333Total

$
284,277

$
284,277

$
1,333


Employment Agreements

During 2010, our named executive officers were employed pursuant to offer letters with us. Each offer letter specifies, among other
things, the named executive officer's initial base salary, bonus opportunity, entitlement to participate in our benefits plans and post-termination benefits and obligations. The
post-termination benefits are described in the section entitled "Potential Payments on Termination and Change of Control" appearing on page 18 of this annual report on
Form 10-K.

Dr. F.
Raymond Salemme has been employed by us as our Chief Executive Officer pursuant to an offer letter, dated May 25, 2004. Dr. Salemme's offer letter was
subsequently amended on December 19, 2008 to comply with the requirements of section 409A of the Internal Revenue Code. Dr. Salemme's offer letter provides for a monthly base
salary. Dr. Salemme's current monthly salary is $29,219, or $350,625 on an annual basis. Pursuant to his offer letter, Dr. Salemme is also eligible for certain other benefits paid for by
us, including, among other things, annual bonuses of up to 40% of his base salary, long-term incentive compensation and health care insurance coverage. Dr. Salemme's employment is
"at will" and not for any specified period of time. Pursuant to the terms of his offer letter, if we terminate his employment without cause or if he terminates his employment for good reason,
Dr. Salemme will be entitled to receive his monthly salary, medical and dental benefits and the vesting of his then-outstanding stock options for 12 months. If we terminate
his employment for cause, Dr. Salemme will not be entitled to any subsequent payments. Dr. Salemme's offer letter required his execution of our standard confidentiality, nondisclosure,
noncompetition and invention assignment agreement.

Scott
M. Horvitz has been employed by us as our Chief Financial Officer pursuant to an offer letter, dated June 28, 2004. Mr. Horvitz's offer letter was subsequently
amended on December 19, 2008

19

---



Table of Contents

to
comply with the requirements of section 409A of the Internal Revenue Code and to provide Mr. Horvitz with severance payments and benefits upon his resignation for good reason
following a
change of control. Mr. Horvitz's offer letter, provides for a monthly base salary. Mr. Horvitz's current monthly salary is $20,984, or $251,805 on an annual basis. Pursuant to his offer
letter, Mr. Horvitz is also eligible for certain other benefits paid for by us, including, among other things, annual bonuses of up to 30% of his base salary, long-term incentive
compensation and health care insurance coverage. Mr. Horvitz's employment is "at will" and not for any specified period of time. Pursuant to the terms of his offer letter, if we terminate his
employment without cause or if he terminates his employment for good reason after a change of control, Mr. Horvitz will be entitled to receive his monthly salary, medical and dental benefits
and the vesting of his then-outstanding stock options for 12 months. If we terminate his employment for cause, Mr. Horvitz will not be entitled to any subsequent payments.
Mr. Horvitz's offer letter required his execution of our standard confidentiality, nondisclosure, noncompetition and invention assignment agreement.

Compensation Committee Interlocks and Insider Participation

Except for Dr. Salemme, none of our executive officers serves as a member of the board of directors or compensation committee,
or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our Board or compensation committee. None of the members of
our compensation committee has ever been our employee or one of our officers.

Compensation Committee Report

The information contained in this report shall not be deemed to be "soliciting material" or "filed" with the
SEC or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended, referred to herein as the Exchange Act, except to the extent that Redpoint Bio Corporation
specifically incorporates it by reference into a document filed under the Securities Act of 1933, as amended, or the Exchange Act.

The
Committee is responsible for evaluating and approving the compensation for the named executive officers. Management has primary responsibility for our financial statements and
reporting process, including the disclosure of executive compensation. The Committee has reviewed and discussed with management the Compensation Discussion and Analysis set forth above. The Committee
is satisfied that the Compensation Discussion and Analysis fairly represents the objectives and actions of the Committee. The Committee has recommended to the Board that the Compensation Discussion
and Analysis be included in this annual report on Form 10-K for filing with the Securities and Exchange Commission.

Submitted by:
The Compensation Committee of the Board of DirectorsRobert Chefitz, Chairman
Allen Bloom, Ph.D.
Leif Kjaergaard, Ph.D.


20

---



Table of Contents

ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

Equity Compensation Plans

The following table provides information with respect to all of our compensation plans under which equity compensation is authorized as
of December 31, 2010.

Plan Category

Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights

Weighted Average
Exercise Price of
Outstanding Options,
Warrants and Rights

Number of Securities
Available for Future
Issuance Under Equity
Compensation PlansEquity compensation plans that have been approved by security holders(1)


9,569,260

$
0.45


6,999,989Equity compensation plans not approved by security holders








Total


9,569,260





6,999,989


---

PRINCIPAL STOCKHOLDERS

The following table and notes thereto set forth information with respect to the beneficial ownership of shares of our common stock as
of March 23, 2011 (except as otherwise indicated below) by (i) each of our directors and director nominees, (ii) each of our executive officers, (iii) our directors and
executive officers as a group, and (iv) each person known to be the beneficial owner of five percent (5%) or more of our common stock. This information is based upon information furnished to us
by each such person and/or based upon public filings with the Securities and Exchange Commission.

The
information regarding beneficial ownership of our common stock has been presented in accordance with the rules of the Securities and Exchange Commission. Under these rules, a person
may be deemed to beneficially own any shares of capital stock as to which such person, directly or indirectly, has or shares voting power or investment power, and to beneficially own any shares of our
capital stock as to which such person has the right to acquire voting or investment power within 60 days through the exercise of any stock option or other right. The percentage of beneficial
ownership as to any person as of a particular date is calculated by dividing (a) (i) the number of shares beneficially owned by such person plus (ii) the number of shares as to which
such person has the right to acquire voting or investment power within 60 days by (b) the total number of shares outstanding as of such date, plus any shares that such person has the
right to acquire within 60 days. Including those shares in the tables does not, however, constitute an admission that the named stockholder is a direct or indirect beneficial owner of those
shares. Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person's spouse) with respect to all shares of
capital stock listed as owned by that person or entity.

21

---



Table of Contents

Unless
otherwise specified, the address of each of the persons set forth below is in care of Redpoint Bio Corporation, 7 Graphics Drive, Ewing, New Jersey 08628.

Beneficial Ownership as of
March 23, 2011Name and Address of Beneficial Owner

Number of Shares(1)

Percentage of
Common Stock(2)Directors and Executive OfficersF. Raymond Salemme, Ph.D.


5,043,026
(3)

5.97
%Scott M. Horvitz


1,579,217
(4)

1.94
%Robert Chefitz


3,997,118
(5)

5.01
%Leif Kjaergaard, Ph.D.


25,000
(6)

*Allen Bloom, Ph.D.


105,000
(7)

*Irwin Scher, M.D.


100,000
(8)

*Richard P. Shanley, CPA


110,000
(9)

*All current directors and executive officers as a group (7 persons)(9)


10,959,361
(10)

12.71
%5% StockholdersCargill, Incorporated


7,268,474
(11)

9.10
%15407 McGinty RoadWest Wayzata, Minnesota 55391Danisco Venture A/S


5,643,143
(12)

7.06
%Langebrogade 1, DK-1001Copenhagen K, DenmarkNJTC Venture Fund SBIC, L.P.


3,997,118
(13)

5.00
%1001 Briggs Road, Suite 280Mt. Laurel, New Jersey 08054S.R. One, Limited


7,455,689
(14)

9.33
%c/o GlaxoSmithKlineOne Franklin PlazaPhiladelphia, PennsylvaniaF. Raymond Salemme, Ph.D.


5,043,026
(3)(3)

5.97
%1970 Timber Lakes DriveYardly, PA 19067


---

22

---



Table of Contents

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

See "Executive Compensation" and "Director Compensation" above for a discussion of director compensation, executive compensation and
our named executive officers' employment agreements, including the Confidential Separation Agreement and General Release the Company entered into with Scott A. Siegel, Ph.D., on February 26,
2009, and the Separation of Employment Agreement and General Release the Company entered into with Robert W. Bryant, Ph.D., on January 9, 2009.

Under
NASDAQ rules, a Director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship which would interfere
with the exercise of independent judgment in carrying out the responsibilities of a Director. Our Board of Directors has determined that with the exception of Dr. Salemme, who serves as our
President and Chief Executive Officer, none of our directors has a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a Director and
that each of these Directors is an "independent director" as defined under Rule 5605(a)(2) of the NASDAQ Stock Market Marketplace Rules.

Review and Approval of Related Party Transactions

Our Board has adopted written policies and procedures for the review, approval or ratification of transactions involving the Company
and any executive officer, director, director nominee, 5% stockholder and certain of their immediate family members (each of whom we refer to as a "related person"). The policy and procedures cover
any transaction involving more than $120,000 with a related person (a "related person transaction") in which the related person has a
material interest and which does not fall under an explicitly stated exception set forth in the applicable disclosure rules of the SEC.

Any
proposed related person transaction must be reported to the Company's Chief Financial Officer. The policy calls for the transaction to be reviewed and, if deemed appropriate,
approved by the Audit Committee. The transaction should be approved in advance whenever practicable. If not

23

---



Table of Contents

practicable,
the Audit Committee will review, and may, if deemed appropriate, ratify the related person transaction. The policy also permits the chairman of the Audit Committee to approve related
person transactions that arise between committee meetings, subject to ratification by the Audit Committee at its next meeting. Any related person transaction that is ongoing in nature will be reviewed
annually.

A
related person transaction will be considered approved or ratified if it is authorized by the Audit Committee or chairman after full disclosure of the related person's interest in the
transaction. The transaction may be approved or ratified only if the Audit Committee determines that the transaction is not inconsistent with the Company's best interests. In considering related
person transactions, the Audit Committee will consider any information considered material to investors and the following factors:



The
policy provides that transactions involving the compensation of our executive officers will be reviewed and approved by the Audit Committee or our Board, in accordance with the Audit Committee's
charter.

ITEM 14.    PRINCIPAL ACCOUNTING FEES AND SERVICES.

The following table summarizes the aggregate fees billed for professional services rendered to us by KPMG LLP, our independent
registered public accounting firm, in fiscal years 2009 and 2010. A description of these fees and services follows the table.

2009

2010Audit Fees

$
200,000

$
200,000Audit-related Fees





Tax Fees

$
12,500

$
29,635All Other Fees





Total


212,500

$
229,635


Audit Fees

Fees for 2010 and 2009 audit services included fees associated with the annual audit of our financial statements and the interim
reviews of Redpoint's quarterly reports on Form 10-Q, notwithstanding when the fees were billed or rendered.

Audit-Related Fees

There were no audit-related fees for either 2010 or 2009.

Tax Fees

For 2010 and 2009, the tax fees were related to tax consulting, tax compliance, tax return preparation and tax planning services.

24

---



Table of Contents

All Other Fees

There were no fees for the category "All Other Services" in 2010 and 2009.

The
Audit Committee has considered whether the provision of these services by KPMG LLP is compatible with maintaining the independence of KPMG LLP. Further, all of the
services provided by KPMG LLP in 2010 were approved in advance in accordance with the Audit Committee's pre-approval policies and procedures described below. The Audit Committee did
not rely on the waiver of pre-approval procedures permitted with respect to de minimus non-audit services under the applicable rules of the SEC for its approval of any of the
services provided by KPMG LLP since their appointment as Redpoint's independent registered public accounting firm in May 2007.

Pre-Approval Policies and Procedures

The Audit Committee has adopted policies and procedures relating to the pre-approval of all audit and non-audit
services to be provided by our independent registered public accounting firm. Under these policies and procedures, the Audit Committee approves in advance the provision of services and fees for such
services that are specifically identified in the independent registered public accounting firm's annual engagement letter for the audits and reviews, in management's annual budget relating to services
to be provided by the independent registered public accounting firm and any amendments to the annual budget reflecting
additional services to be provided by or higher fees of the independent registered public accounting firm. All other services to be provided by the independent registered public accounting firm are
pre-approved by the Audit Committee as they arise. The Chairman of the Audit Committee has been delegated authority to pre-approve services in accordance with these policies
and procedures. The Chairman is to report any such approval of services to the Audit Committee at its next meeting. The Audit Committee considers, among other things, whether the provision of such
audit or non-audit services is consistent with applicable regulations regarding maintaining auditor independence, whether the provision of such services would impair the independent
registered public accounting firm' independence and whether the independent registered public accounting firm is best positioned to provide the most effective and efficient service.

25

---





Table of Contents

PART IV

ITEM 15.    EXHIBITS, FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES

31.1

Certification Pursuant to Rule 13a-14(a) and 15d-14(a) of Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).*31.2

Certification Pursuant to Rule 13a-14(a) and 15d-14(a) of the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).*32.1

Certification Pursuant to 18 U.S.C. Section 1350 (Chief Executive Officer).*32.2

Certification Pursuant to 18 U.S.C. Section 1350 (Chief Financial Officer).*


---

26

---



Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized this 12th day of May, 2011.

REDPOINT BIO CORPORATIONBy:

/s/ F. RAYMOND SALEMME, PH.D. F. Raymond Salemme, Ph.D. President, Chief Executive Officer and Director (Principal Executive Officer)


Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on
the dates indicated.

Signature

Title

Date/s/ F. RAYMOND SALEMME F. Raymond Salemme

President, Chief Executive Officer and Director (Principal Executive Officer)

May 12, 2011/s/ SCOTT HORVITZ Scott Horvitz

Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)

May 12, 2011/s/ ALLEN BLOOM Allen Bloom

Director

May 12, 2011/s/ ROBERT CHEFITZ Robert Chefitz

Director

May 12, 2011/s/ LEIF KJAERGAARD Leif Kjaergaard

Director

May 12, 2011/s/ IRWIN SCHER Irwin Scher

Director

May 12, 2011/s/ RICHARD SHANLEY Richard Shanley

Director

May 12, 2011


27

---



Table of Contents

EXHIBIT INDEX

31.1

Certification Pursuant to Rule 13a-14(a) and 15d-14(a) of Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).*31.2

Certification Pursuant to Rule 13a-14(a) and 15d-14(a) of the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).*32.1

Certification Pursuant to 18 U.S.C. Section 1350 (Chief Executive Officer).*32.2

Certification Pursuant to 18 U.S.C. Section 1350 (Chief Financial Officer).*


---

28

---